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OBJECTIVES: To study the role of angiogenesis and cyclooxygenase-2 expression in cartilaginous tumors and
correlate these factors with prognosis.
INTRODUCTION: For chondrosarcoma, the histological grade is the current standard for predicting tumor outcome.
However, a low-grade chondrosarcoma can follow an aggressive course—as monitored by sequential imaging
techniques—even when it is histologically indistinguishable from an enchondroma. Therefore, additional tools are
needed to help identify the biological potential of these tumors. The degree of angiogenesis that is induced by the
tumor could assist in this task. Angiogenesis can be quantified by measuring the expression of vascular endothelial
growth factor and CD34, and cyclooxygenase-2 can induce angiogenesis by stimulating the production of pro-
angiogenic factors.
METHODS: In total, 21 enchondromas and 58 conventional chondrosarcomas were studied by examining the clinical
and histopathological findings in conjunction with the immunostaining markers of angiogenesis and cycloox-
ygenase-2 expression.
RESULTS: The significant variables that were associated with poor outcome were 1) higher-grade chondrosarcomas,
2) tumors that developed in flat bones, and 3) over-expression of CD34 (with a median count that was higher than
5.9 vessels in 5 high power fields). Moreover, CD34 expression (measured using the Chalkley method) revealed
significantly higher microvessel density in flat bone chondrosarcomas.
DISCUSSION: Previous studies have shown a positive correlation between Chalkley microvessel density and
histological grade; however, in our sample, we found that the former is predictive of the outcome.
Chondrosarcomas in flat bones have been shown to correlate with a poor prognosis. We also found that CD34
microvessel density values were significantly higher in flat-bone chondrosarcomas. This could explain—at least in
part—the more aggressive biological course that is taken by these tumors.
CONCLUSIONS: These results provide evidence that CD34 microvessel density in chondrosarcomas can be helpful in
predicting patient outcome and may add to our understanding of chondrosarcoma pathogenesis.
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INTRODUCTION
Among bone tumors, cartilage-producing tumors rank as
the third most frequent type, representing 30% of benign
tumors and 10–20% of malignant tumors.1,2 The World
Health Organization (WHO) Classification of Bone Tumors
(2002), which is based on the histological grade of the
tumor, has been accepted as the standard for predicting
tumor outcome.3,4 The histological grading system for
chondrosarcomas (CSs) categorizes these tumors into three
grades that are based on cellularity, nuclear atypia, and
pleomorphism.4 Low-grade CSs tend to grow slowly and
are associated with a 90% five-year survival rate but can
recur and metastasize. In contrast, high-grade tumors have a
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higher incidence of metastasis and a 45% five-year survival
rate.3-6 In some borderline tumors (i.e., a grade 1 CS),
distinguishing a CS from an enchondroma (EC) may be
difficult when using only a routine histopathological
examination, as the current diagnostic criteria are not
definitive. Furthermore, these tumors have a broad array
of clinical, radiographic, and histological presentations that
cause difficulties in both diagnosis and treatment.3-7 Thus,
it is important to establish additional tools that could
help predict a tumor’s biological potential. The degree of
angiogenesis that the tumor elicits might assist in making
this distinction.
Angiogenesis is a fundamental step in both neoplastic
transformation and the regulation of tumor growth, as
demonstrated by Folkman8 and Dvorak et al.9 The interaction
of vessels with cartilaginous tissue is not a physiological step,
except during skeletal development. For example, in enchon-
dral ossification (the period in which the growth plate is
active), vessels can be seen penetrating the zones of
hypertrophied cartilage during matrix ossification.10,11
However, normal adult cartilage is avascular. Thus, the
presence of vessels within cartilaginous tissue is associated
with pathological conditions, such as osteoarthritis and
tumors.10,11 Angiogenesis (or neoangiogenesis) can be quan-
tified by measuring the expression of certain molecules.
Vascular endothelial growth factor (VEGF) is one of the
most important angiogenic factors that have been described.
Among its many functions are the formation, organization,
and migration of blood vessels. VEGF also promotes the
degradation of soft tissues around the sprouting endothe-
lium and increases the permeability of venules. An inc-
rease in VEGF staining has been described in many
epithelial, germ cell, lymphoid, melanocytic, and mesench-
ymal tumors.12-16
CD34 is a surface glycophosphoprotein that is expressed
in small-vessel endothelial cells and is associated with
angiogenesis.16-20
Cyclooxygenases (COXs) are enzymes that catalyze
the synthesis of prostaglandins from arachidonic acid.
Cyclooxygenase-2 (COX-2) is associated with inflammatory
and mitogenic stimuli, resulting in increased prostaglandin
synthesis in both inflamed and neoplastic tissues.21-23 COX-
2 also plays an important role in carcinogenesis, as it can
induce angiogenesis by stimulating the production of pro-
angiogenic factors, such as VEGF;21-23 in addition, COX-2
can inhibit tumor cell apoptosis and immune surveillance,
thus increasing the tumor’s invasive and metastatic poten-
tial.21-23,25 Indeed, recent studies of various human tumors
showed that COX-2 over-expression is associated with poor
prognosis.21 In musculoskeletal tumors (e.g., osteosarcomas,
rhabdomyosarcomas, and CSs), studies of COX-2 over-
expression have yielded conflicting results.21-29
In fact, neovascularization is only one of the many
elements involved in neoplastic transformation and the
progression of a tumor to a higher histological grade.
However, because inhibiting angiogenesis is so important in
the preservation of intact cartilage (as seen in the osteoar-
thritis therapeutic approach),10,11,15,16 it is possible that the
lack of this inhibition is a significant component in the
pathogenesis of cartilage tumors.
The present report is a retrospective study of 21 ECs and
58 conventional CSs, in which we addressed the clinical and
follow-up data and histopathological findings with regard
to immunostaining for markers of angiogenesis and COX-2
expression. The aim of this study was to evaluate the value
of these findings as a prognostic tool in CSs and as a
possible aid in the differential diagnosis between an ECs
and a low-grade CSs.
MATERIALS AND METHODS
Patients and tumor samples
From 1988 through 2007, 141 patients with a primary EC
or CS were admitted to the University Hospital – Unicamp
(Campinas-Brazil) and Centro Me´dico de Campinas (Brazil).
The tumor specimens were routinely fixed in 10% formalin
and later decalcified with hydrochloric acid and ethylene-
diaminetetraacetic acid. The embedded tumor tissue from
each patient was obtained from the Department of Path-
ology. The clinical, radiographic, and follow-up information
were obtained from the patients’ medical records. The
routine staining of the tumor sections was reviewed to
confirm the diagnosis. The histological grade (on a scale of 1
to 3) of each CS was determined based on nuclear size and
staining (hyperchromasia) and cellularity according to the
WHO Classification of Bone Tumors (2002).1
Pathological material with insufficient tissue samples
for new cuts or in poor fixative condition (n = 54) and
chondrosarcoma variants (mesenchymal: n = 4; de-differen-
tiated: n = 2; clear cell: n = 2), were excluded from the
analysis. Therefore, a total of 79 patients (30 men and 49
women, ranging from 5 to 87 years of age, with a median
age of 42 years) entered the study. There was no loss of
follow-up data. The patient data are summarized in Table 1.
Twenty-one ECs that developed in the long (n = 5) and
short bones (n = 16) were studied. Among the CSs were 31
grade 1 CSs that developed in the long (n = 23) and flat
bones (n = 8). Twenty-four grade 2 CSs developed in the
long (n = 18) and flat bones (n = 6), and 3 grade 3 CSs
developed in the long (n = 1) and flat bones (n = 2). With the
goal of correlating the clinical and histological results, the
patients were divided into the following three groups:
group I (n = 21) comprised the patients with an EC; group II
(n = 31) comprised the patients with a grade 1 CS; and
group III (n = 27) comprised the patients with a grade 2 or
3 CS.
Because flat-bone CSs are associated with poor prog-
nosis,1 the benign and malignant tumor anatomical sites
were also divided into three groups. Seventeen tumors
(16 ECs and 1 high-grade CS) developed in small bones
(metacarpal bone, n = 11; hand phalanx, n = 4; metatarsal
bone, n = 1; calcaneus, n = 1). Forty-eight tumors (5 ECs and
43 CSs) developed in long bones (femur, n = 18; fibula, n = 3;
tibia, n = 10; humerus, n = 13; radius, n = 3; lumbar vertebra,
n = 1). Fourteen tumors (all CSs) developed in flat bones
(ribs, n = 6; scapula, n = 2; pelvis, n = 6).
All of the ECs (n = 21) were treated with curettage. The
CSs were removed by either wide resection or amputation,
with a wide margin in 12 cases, a marginal resection in 26
cases, and an intralesional resection or curettage in 18 cases
(all 18 of which were grade 1 CS cases).30 Instead of surgery,
two extremely large pelvic tumors (in the sacrum and iliac
bone) were treated using chemotherapy and/or radio-
therapy after establishing the diagnosis by biopsy. Four of
the patients underwent chemo/radiotherapy for local
recurrence and metastasis after undergoing a marginal
resection. Chondrosarcoma size and the adequacy of the
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surgical margins were excluded from analysis, as 18 of the
58 CS patients were treated with curettage.
The follow-up interval was recorded from the time of the
surgery until January 2009. The minimum follow-up period
was 24 months (or shorter in cases of death), and the median
follow-up was 77 months (with a range of 4-250 months).
Immunohistochemical technique
The primary antibodies that were used included anti-
CD34 (Mo a Hu CD34 Class II, Clone QBEnd 10, Dako
Cytomation, Carpenteria, CA, USA) at a dilution of 1550,
anti-VEGF (A-20 rabbit polyclonal IgG, 200 mg/ml, Santa
Cruz Biotech., Inc, Santa Cruz, CA, USA) at a dilution of
15200, and anti-COX-2 (Cyclooxygenase-2 antibody clone-
4h12, Diagnostic Byosystem, Pleasanton, CA, USA) at a
dilution of 1550. Epitope retrieval was achieved by steaming
with citrate buffer (at 95 C˚). The EnVision + Dual Link
System HRP polymer (Dako) was used as a reaction
amplifier. The antibody complex was visualized with 3,39-
diaminobenzidine tetrahydrochloride (DAB) staining
according to the manufacturer’s instructions. The sections
were counterstained with Mayer hematoxylin. The appro-
priate negative and positive controls were included in each
assay.
Immunohistochemical analysis
All of the immunostained sections were evaluated
simultaneously (using a double-headed microscope) by
two investigators (EMIA and FFC) who were unaware of
the clinical status of the patient being studied.
With regard to COX-2, a consensus judgment was
adopted as the proper tumor immunohistochemical score
according to the method of Endo et al.,22 with adaptations
characterized by the mean of the proportion of stained
tumor cells in 5 ‘‘hot-spot’’ high-power fields (at 400x
magnification) as follows: 0 = no stained tumor cells; 1+ =
less than 10% of all tumor cells stained; 2+ = 10–50% of all
tumor cells stained; and 3+ = more than 50% of all tumor
cells stained.
For VEGF, cellularity was quantified by counting the
relative number of immunostained cells per 5 ‘‘hot-spot’’
high-power fields (HPFs) (at 400x magnification) and was
expressed as a percentage of the total number of neoplastic
cells according to the method of Ayala et al.12
For the CD34 analysis, the sections were scanned using a
low-power view (at 50x magnification). Five areas display-
ing the highest number of immunostained microvessels (i.e.,
hot-spots) were identified.17,18 Next, one 400x microscopic
field (corresponding to an area of 0.1449 mm2) was chosen
within each hot-spot. A 25-point Chalkley eyepiece graticule
(Leitz Orthoplan, Leica) was applied to each selected
hot-spot field (corresponding to a Chalkley grid area of
0.041 mm2). The graticule was positioned such that the
immunostained vessels hit the maximum number of points.
The final Chalkley count for an individual tumor was taken
as the mean value of the five graticule counts. The generally
accepted criteria for determining a vessel’s profile17,18 were
followed and included any stained endothelial cells or
endothelial cell clusters that were separated from the
adjacent microvessels. A visible lumen was not a require-
ment for a structure to be counted as a microvessel. Necrotic
or sclerotic areas within the tumor and non-tumor areas that
were adjacent to the tumor were excluded from the vessel
counts.31-33
Statistical analysis
Chi-squared or Fisher’s tests were used to compare
outcome, gender, site, follow-up span, and COX-2 expres-
sion. For the VEGF and CD34 results, Mann-Whitney test,
Kruskal-Wallis test or analysis of variance (ANOVA) with
transformation by ranks was used, followed by Tukey’s test
to identify differences when necessary. To test the linear
association between two immunomarkers, the Spearman
correlation coefficient was determined. A multiple logistic
regression analysis (the generalized log model) was used to
identify factors that differentiate the histological grade of
the tumor. The process of selecting the variables that were
used was stepwise. The level of significance for the
statistical tests was set at p,0.05. The data analysis was
performed using the SAS System for Windows version 9.2
(SAS Institute Inc., Cary, NC, USA).
RESULTS
The results are summarized in Tables 1 and 2.
The following 14 patients had poor outcomes: three in
group II (metastasis: n = 1; local recurrence: n = 2) and 11 in
group III (local recurrence: n = 4; death: n = 7). None of the
ECs recurred. None of the patients whose CS was treated
with curettage presented a tumor recurrence or poor
outcome.
There were no significant differences among the three
groups with regard to the duration of follow-up (p= 0.7431).
A poor outcome was significantly associated with the
following: 1) moderate/high-grade CS (p,0.0001); 2) tu-
mors that developed in a flat bone (p,0.0001); and 3) over-
expression (p,0.02) of CD34 (when the number of immu-
nostained vessels was higher than the median of 5.9 vessels
in 5 high-power fields) (Figures 1A and B). No significant
correlations were found between outcome and age
Table 1 - Correlation between variables in groups I, II, and
III.
Group I
(n = 21 ECs)
Group II (n = 31
Low-Grade
CSs)
Group III (n = 27
Moderate/High-
Grade CSs)
Gender
Male 7 (33.33%) 13 (41.93%) 10 (37.03%)
Female 14 (66.67%) 18 (58.07%) 17 (62.97%)
Mean age at Dx (years) 29.6 43 50
Follow-up (months) 98 66 71
Site
Small bone 16 (76.2%) 0 1 (3.7%)
Long bone 5 (23.8%) 23 (74.20%) 20 (74.1%)
Flat bone 0 8 (25.8%) 6 (22.22)
COX-2
No expression 2 (9.5%) 20 (64.5%) 15 (55.56%)
,10% 9 (42.9%) 7 (22.6%) 6 (22.22)
10-50% 8 (38.1%) 4 (12.9%) 3 (11.11%)
.50% 2 (9.5%) 0 3 (11.11%)
VEGF
#10.5% 11 (52.38%) 17 (54.84%) 14 (51.85%)
.10.5% 10 (47.69%) 14 (45.16%) 13 (48.15%)
CD34
#5.9 21 (100%) 27 (87%) 20 (74.1%)
.5.9 0 4 (13%) 7 (25.9%)
Outcome 100% cured 3 (9.6%) poor 11 (40.7%) poor
Dx: diagnosis; ECs: enchondromas; CSs: chondrosarcomas; Mod: moderate.
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(p= 0.1966), gender (p= 0.7293), COX-2 expression
(p= 0.3364), or VEGF expression (p= 0.2094). An over-
expression of VEGF (when the percentage of immunos-
tained cells was higher than the median of 10.5% in five
high-power fields) was found in 48% of low-grade CSs
(group II) and in 59% of moderate/high-grade CSs (group
III).
None of the variables proved useful for differentiating
between low-grade CSs and ECS (p= 0.7152).
A multivariate analysis of CD34 immunostaining (using
Mann-Whitney, ANOVA, and Tukey’s tests) revealed a
positive association between higher microvessel density
(MVD) and flat bone sites (p,0.01). Indeed, flat bone CSs
(Figure 1B) had a mean of 6.1 CD34-positive vessels in the
Chalkley count compared with 4.7 and 4.6 CD34-positive
vessels in the long and small bones, respectively.
Although COX-2 expression was not correlated with
patient outcome, its over-expression (Figure 1C) (more than
10% positive COX-2 cells in five high-power fields) was
positively correlated (p,0.02) with increased CD34-positive
MVD (using an ANOVA test followed by the Kruskal-
Wallis test). Among the EC cases, we found that 19/21
(90%) of the tumors stained positively for COX-2 (Fig. 1D).
In 10 of the 21 ECs (47%), an over-expression (i.e., .10% of
positive cells) was found; VEGF over-expression was found
in 13 (61%) of the ECs. Intra-tumoral CD34-positive vessels
were found in 100% of the ECs but displayed weak CD34
expression (none had a Chalkley count above 5.5).
DISCUSSION
Histological grading of CSs is considered to be the
most useful predictor of outcome,1,3,4 but this is a sub-
jective procedure, and the current criteria are not defini-
tive.5,6 Therefore, supplemental methods for assessing the
prognosis of CS patients have been sought and include the
evaluation of DNA synthesis and content; flow cytometry
using molecular markers, such as p53 and MIB-1; cytoge-
netic features; histomorphometry; and radiographic classi-
fications. Nevertheless, none of these methods is considered
to be definitive.1,3-7
The present study provides immunohistochemical evi-
dence that MVD—as evaluated by CD34 staining—is
significantly associated with poor prognosis. Our results
differ from those of Nakagawa et al.,25 who found no
correlation between CD34 expression and outcome. The two
additional predictive variables that we identified (i.e.,
histological grade and tumor site in flat bones) are well
known in the medical literature.1,4,5 However, in our study,
we also found that CD34 positive MVD was significantly
higher in flat bone CSs. In animal experiments, flat and long
bones had the same density of vessels.34 However, in adults,
flat bones have functional bone marrow that contains stem
cells and produces many growth factors16 that could elicit
tumor angiogenesis.
The role of COX-2 in cartilage tumors is controversial.
Endo et al. in 2006 and Schrage et al. in 201022,23 have
reported that COX-2 over-expression is associated with poor
Table 2 - Correlation between variables in groups II
(grade I CSs) and III (high-grade CSs).
Outcome Good (n=44) Poor (n= 14) p-value
Gender 0.7293*
Male 18 (40.1%) 5 (35.7%)
Female 26 (39.9%) 9 (64.3%)
Age (years) 0.1966*
#51 28 (63.6%) 7 (50%)
.51 16 (36.4%) 7(50%)
Histological Grade ,0.0001*
Grade 1 28 (63.6%) 3 (21.4%)
Grade 2 or 3 16 (36.4%) 11 (78.6%)
Site ,0.0001*
small bone 1 (2.3%) 0
long bone 36 (81.8%) 7 (50%)
flat bone 7 (15.9%) 7 (50%)
CD34 MVD 0.0104¥
#5.9 37 (84%) 7 (50%)
.5.9 7 (16%) 7 (50%)
COX-2 0.3364*
no expression 28 (63.6%) 7 (50%)
,10% 10 (22.7%) 3 (21.4%)
10-50% 5 (11.3%) 2 (14.3%)
.50% 1 (2.4%) 2 (14.3%)
VEGF expression 0.2094¥
#10.5% 22 (50%) 9 (64.3%)
.10.5% 22 (50%) 5 (35.7%)
*- Fischer test.
¥ - Mann-Whitney and ANOVA test.
Figure 1 - (A) A grade I femur chondrosarcoma (CS) with low
CD34 microvascular density (CD34 positive MVD). Bar =
0.02 mm. (B) A grade II iliac bone CS with high CD34 positive
MVD. Bar = 0.04 mm. A magnified view is shown in the inset
(bar = 0.02 mm). (C) A grade 3 humerus CS. Bar = 0.02 mm.
Bizarre cells are shown in the inset (bar = 0.01 mm) with diffuse
strong immunoreactivity to COX-2 antibody. (D) A hand phalanx
enchondroma with uniform and diffuse immunoreactivity to
COX-2 antibody. Bar = 0.02 mm.
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prognosis in CSs. Our results are in line with those of Sutton
et al.,21 who studied 32 cartilaginous tumors by Western
blot analysis and found no statistical correlation between
the expression of COX-2 and the following variables: age,
sex, stage, anatomical site, metastasis development, or
survival rate. In addition, Nakagawa et al.25 studied 101
CS specimens and found no correlation between COX-2
expression and prognosis. We previously studied 53 CSs
(seven of which were unconventional and included four
mesenchymal, two de-differentiated and one clear-cell).35 In
the previous sample, we found that a COX-2 expression
frequency above 50% was associated with poor prognosis;
all of the six patients with either mesenchymal or de-
differentiated CSs died within 24 months of their diagnosis.
In the present study, we added 12 additional conventional
CS patients and excluded the unconventional tumors
from the sample and found no significant correlation
between COX-2 expression and outcome. Another differ-
ence between our findings and those of Endo et al.22 was
that they did not find any COX-2 staining in enchondromas,
whereas 90% of our enchondroma specimens had positive
COX-2 staining.
Contradictory results have also been obtained from study-
ing other bone tumors, such as osteosarcomas. Xu et al.26
found that COX-2 over-expression was associated with a
better prognosis. In contrast, Dinckens et al.27 found no
correlation between COX-2 over-expression and patient
outcome. Finally, Masi et al.28 and Liao et al.29 reported that
cases of osteosarcoma had worse prognosis and decreased
patient survival rates whether COX-2 was overexpressed. We
suggest the following two reasons for these discordant
results: 1) the COX-2 antibody clone that we used was
different from that used by Endo et al.; and/or 2) any
problems with the fixation or decalcification of the samples
could have biased the results. Nevertheless, we found a
positive correlation between CD34 positive MVD and COX-2
expression, which is in line with the well-known relationship
between COX-2 and angiogenesis. Therefore, this enzyme
might have at least an indirect role in patient prognosis.
With respect to VEGF expression, our quantitative results
are similar to those of Ayala et al.12 and Kalinski et al.,13,14
which were descriptive studies that found a higher rate of
VEGF expression in moderate- and high-grade CSs. In our
sample, no significant correlation was observed between
VEGF expression and outcome.
CONCLUSIONS
Chalkley MVD—as evaluated through CD34 antibody
expression—may be a useful tool to help predict patient
outcome in chondrosarcoma (CS) cases. These data can be
considered for selective therapeutic inhibitory targeting.
The higher MVD in flat bone CSs could explain the poorer
outcome of these tumors relative to long/short bone CSs.
None of the variables that were examined in this study were
found to be useful in distinguishing a low-grade chondro-
sarcoma from an enchondroma.
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